Table 3.
Survey Responses from the Final-Year Pharmacy Students
| Survey Questions | Number of Respondents (%) | |||
|---|---|---|---|---|
| Strongly Agree/Agree | Neutral | Strongly Disagree/Disagree | No Response | |
| Perception of the clinical relevance of pharmacogenomics | ||||
| Pharmacogenomics is an integral part of the pharmacy profession. | 214 (63.1) | 67 (19.8) | 28 (8.26) | 30 (8.85) |
| Pharmacogenomics may be an integral part of my practice as a pharmacist. | 205 (60.5) | 62 (18.3) | 42 (12.4) | 30 (8.85) |
| I may encounter pharmacogenomics-related questions during my practice as a pharmacist. | 234 (69.0) | 45 (13.3) | 29 (8.55) | 31 (9.14) |
| Pharmacogenomics is a useful tool that pharmacists and medical professionals can use to optimize medication efficacy and/or prevent adverse events. | 273 (80.5) | 27 (7.96) | 9 (2.65) | 30 (8.85) |
| Attitudes toward pharmacogenomics education | ||||
| Pharmacogenomics has been a relevant part of my doctor of pharmacy curriculum. | 136 (40.1) | 88 (26.0) | 96 (28.3) | 19 (5.60) |
| Pharmacogenomics should be covered in detail for all colleges and schools of pharmacy. | 239 (70.5) | 67 (19.8) | 13 (3.83) | 20 (6.00) |
| Final-year (P4) pharmacy students should be required to have substantial knowledge of pharmacogenomics prior to graduation. | 175 (51.6) | 97 (28.6) | 48 (14.2) | 19 (5.60) |
| Postgraduation, I intend to read up on pharmacogenomics especially on how it influences my practice and/or specialty. | 188 (55.5) | 81 (23.9) | 51 (15.0) | 19 (5.60) |
| Readiness to use pharmacogenomics knowledge in practice | ||||
| I know at least 10 medications that require or are recommended to have pharmacogenomics testing as per the Food and Drug Administration. | 108 (31.9) | 55 (16.2) | 150 (44.2) | 26 (7.67) |
| I am able to recommend the appropriate pharmacogenomics test(s) for the medications that require it. | 72 (21.2) | 79 (23.3) | 161 (47.5) | 27 (7.96) |
| I am able to accurately interpret pharmacogenomics tests. | 91 (26.8) | 75 (22.1) | 147 (43.4) | 26 (7.67) |
| Based on the results of a pharmacogenomics test, I am able to recommend alternative therapies or dose changes when required. | 107 (31.6) | 82 (24.2) | 124 (36.6) | 26 (7.67) |
| I am aware of the Clinical Pharmacogenetics Implementation Consortium’s guidelines on how to use genetic information to guide drug therapy selection/dosing. | 55 (16.2) | 48 (14.2) | 209 (61.7) | 27 (7.96) |